Long-Term Administration of Beraprost Sodium for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease
スポンサーリンク
概要
- 論文の詳細を見る
Pulmonary arterial hypertension (PAH) is often associated with congenital heart disease (CHD). Acute administration of beraprost reduces pulmonary vascular resistance in patients with idiopathic PAH and PAH associated with CHD; however, little is known about whether or not long-term treatment with oral beraprost benefits these patients. We report the case of a patient suffering from severe PAH associated with large patent ductus arteriosus (PDA), who was considered to be ineligible for PDA closure using a conventional treatment strategy. Eventually, long-term administration of oral beraprost ameliorated the degree of PAH and the patient subsequently underwent successful closure of the PDA.
論文 | ランダム
- 57.PS(polysaccharide)をcarrierとした気管支動脈内制癌剤注入療法 : 実験的研究(第42回日本肺癌学会関西支部会)
- 44.肺癌と他臓器重複癌の手術症例の検討(第42回日本肺癌学会関西支部会)
- 31.術前の化学療法が著効を示した扁平上皮癌の1例(第42回日本肺癌学会関西支部会)
- 6.石灰化膿胸に関連して発生したと思われる胸壁悪性腫瘍の1例(第42回日本肺癌学会関西支部会)
- 53. 肺剥皮術を伴った高齢者肺癌切除例の経験(第41回 日本肺癌学会関西支部会)